Trial Profile
An Open-label, Single-site, One-sequence Cross-over Study to Assess the Relative Bioavailability of TPV/r 500 mg/200 mg at Steady State When TPV and RTV Are Administered as Oral Solutions vs. Capsules in the Fed and Fasted State.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Tipranavir (Primary) ; Ritonavir
- Indications HIV-1 infections
- Focus Pharmacokinetics
- Sponsors Boehringer Ingelheim
- 02 Sep 2014 New trial record